Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis
暂无分享,去创建一个
Chengjie Xiong | Max Kuhn | Jingxia Liu | Holly Soares | David M. Holtzman | Anne M. Fagan | A. Fagan | D. Holtzman | M. Kuhn | H. Soares | C. Xiong | R. Perrin | K. Bales | E. Pickering | R. Craig-Schapiro | Rebecca Craig-Schapiro | Richard J. Perrin | Jingxia Liu | T. P. Misko | Eve H. Pickering | Kelly R. Bales | Thomas P. Misko
[1] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[2] M. Greenberg,et al. β-Amyloid Induces Neuronal Apoptosis Via a Mechanism that Involves the c-Jun N-Terminal Kinase Pathway and the Induction of Fas Ligand , 2001, The Journal of Neuroscience.
[3] Reinhard Schliebs,et al. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and β-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain , 2009, International Journal of Developmental Neuroscience.
[4] K. Blennow,et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. , 2007, Journal of Alzheimer's disease : JAD.
[5] J. Melchor,et al. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[6] S. Strickland,et al. Fibrinogen and β-Amyloid Association Alters Thrombosis and Fibrinolysis: A Possible Contributing Factor to Alzheimer's Disease , 2010, Neuron.
[7] S. Christakos,et al. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[8] G. Waldemar,et al. A Novel Panel of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Alzheimer’s Disease versus Normal Aging and Frontotemporal Dementia , 2007, Dementia and Geriatric Cognitive Disorders.
[9] R. Pearson,et al. Accumulation of calbindin in cortical pyramidal cells with ageing; a putative protective mechanism which fails in Alzheimer's disease , 2001, Neuropathology and applied neurobiology.
[10] W. Sheu,et al. Genotype and Plasma Concentration of Cystatin C in Patients with Late-Onset Alzheimer Disease , 2007, Dementia and Geriatric Cognitive Disorders.
[11] J. Friedman. Greedy function approximation: A gradient boosting machine. , 2001 .
[12] Brian J Cummings,et al. The induction of the TNFalpha death domain signaling pathway in Alzheimer's disease brain. , 2003, Neurochemical research.
[13] Gunhild Waldemar,et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. , 2007, Archives of neurology.
[14] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[15] J. Melchor,et al. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. , 2007 .
[16] Eric R. Ziegel,et al. The Elements of Statistical Learning , 2003, Technometrics.
[17] Jing Zhang,et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. , 2005, Journal of Alzheimer's disease : JAD.
[18] N. Seeds,et al. Plasminogen activator activity is inhibited while neuroserpin is up‐regulated in the Alzheimer disease brain , 2009, Journal of neurochemistry.
[19] A. Burns. Clinical diagnosis of Alzheimer's disease , 1991 .
[20] O. Combarros,et al. Low serum VEGF levels are associated with Alzheimer's disease , 2007, Acta neurologica Scandinavica.
[21] S. Schmidt,et al. Binding of cystatin C to Alzheimer’s amyloid β inhibits in vitro amyloid fibril formation , 2004, Neurobiology of Aging.
[22] A. Fagan,et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.
[23] Rena Li,et al. Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. , 2010, Journal of Alzheimer's disease : JAD.
[24] K. Titani,et al. Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. , 2000, Biochimica et biophysica acta.
[25] J. Melchor,et al. The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-β (Aβ) Degradation and Inhibits Aβ-Induced Neurodegeneration , 2003, The Journal of Neuroscience.
[26] E. Tangalos,et al. Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .
[27] D. Green,et al. Metalloproteinase Shedding of Fas Ligand Regulates β-Amyloid Neurotoxicity , 2002, Current Biology.
[28] P. Carmeliet,et al. Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms , 2007, Neurobiology of Disease.
[29] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[30] Christian Humpel,et al. Chromogranin peptides in Alzheimer's disease , 2004, Experimental Gerontology.
[31] Henrik Zetterberg,et al. Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease , 2009, PloS one.
[32] D. Hochstrasser,et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.
[33] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[34] A. Grubb,et al. Cystatin C reduces the in vitro formation of soluble Aβ1‐42 oligomers and protofibrils , 2007, Scandinavian journal of clinical and laboratory investigation.
[35] J Philip Miller,et al. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI , 2006, Neurology.
[36] H. Hinterhuber,et al. Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other Dementias , 2005, Dementia and Geriatric Cognitive Disorders.
[37] David M Holtzman,et al. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease , 2007, Proteomics. Clinical applications.
[38] M. Weiner,et al. Relationships between biomarkers in aging and dementia , 2009, Neurology.
[39] Bruce R. Kowalski,et al. Partial least-squares path modelling with latent variables , 1979 .
[40] Der-Zen Liu,et al. Hemorheological Mechanisms in Alzheimer's Disease , 2007, Microcirculation.
[41] K. Blennow,et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.
[42] C. Cotman,et al. Fas and Fas Ligand are associated with neuritic degeneration in the AD brain and participate in β-amyloid-induced neuronal death , 2003, Neurobiology of Disease.
[43] B. Hyman,et al. Serum cystatin C and the risk of Alzheimer disease in elderly men , 2008, Neurology.
[44] V. Mathura,et al. Alzheimer’s β‐amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR‐2 , 2010, Journal of neurochemistry.
[45] Murray Grossman,et al. Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment , 2010, Acta Neuropathologica.
[46] Barbara Borroni,et al. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. , 2006, Rejuvenation research.
[47] M. Mattson,et al. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[48] A. Smith,et al. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. , 1998, Alzheimer disease and associated disorders.
[49] N. Bresolin,et al. VEGF genetic variability is associated with increased risk of developing Alzheimer's disease , 2009, Journal of the Neurological Sciences.
[50] K. Blennow,et al. Local and systemic GM‐CSF increase in Alzheimer's disease and vascular dementia , 2001, Acta neurologica Scandinavica.
[51] J. Philip Miller,et al. Combining Correlated Diagnostic Tests: Application to Neuropathologic Diagnosis of Alzheimer’s Disease , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[52] Norman Relkin,et al. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease , 2007, Annals of neurology.
[53] M. Staufenbiel,et al. Cystatin C modulates cerebral beta-amyloidosis. , 2007, Nature genetics.
[54] Kaj Blennow,et al. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. , 2003, Brain research. Molecular brain research.
[55] D. Green,et al. Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity. , 2002, Current biology : CB.
[56] R. S. Sloviter,et al. Calbindin-D28k immunoreactivity and selective vulnerability to ischemia in the dentate gyrus of the developing rat , 1993, Brain Research.
[57] S. Keleş,et al. Sparse partial least squares regression for simultaneous dimension reduction and variable selection , 2010, Journal of the Royal Statistical Society. Series B, Statistical methodology.
[58] D. Radvinsky,et al. Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. , 2007, Nature genetics.
[59] A. Fagan,et al. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.
[60] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[61] Anders Wallin,et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia , 2002, Neurobiology of Aging.
[62] M. Riepe,et al. Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus? , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[63] M. Mattson,et al. Evidence for calcium-reducing and excitoprotective roles for the calcium-binding protein calbindin-1328k in cultured hippocampal neurons , 1991, Neuron.
[64] John Calvin Reed,et al. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons. , 1996, Molecular pharmacology.
[65] Trevor Hastie,et al. Class Prediction by Nearest Shrunken Centroids, with Applications to DNA Microarrays , 2003 .
[66] Y. Nakano,et al. Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia. , 2009, Journal of atherosclerosis and thrombosis.
[67] S. Ha,et al. Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease , 2007, BMC neurology.
[68] Albert Hofman,et al. Fibrinogen Is Associated With an Increased Risk of Alzheimer Disease and Vascular Dementia , 2005, Stroke.
[69] K. Blennow,et al. CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.
[70] J. Becker,et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study , 2008, Neurology.
[71] G. Brewer,et al. Age-related differences in NFκB translocation and Bcl-2/Bax ratio caused by TNFα and Abeta42 promote survival in middle-age neurons and death in old neurons , 2008, Experimental Neurology.
[72] C. Laske,et al. Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease. , 2009, The international journal of neuropsychopharmacology.
[73] F. Jessen,et al. The Role of Macrophage Migration Inhibitory Factor in Alzheimer’s Disease , 2010, Molecular medicine.
[74] Kaj Blennow,et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients , 2002, Neuroreport.
[75] Yan Liu,et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.
[76] Chengjie Xiong,et al. YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.
[77] R. Tibshirani,et al. Flexible Discriminant Analysis by Optimal Scoring , 1994 .
[78] Brian J Cummings,et al. The Induction of the TNFα Death Domain Signaling Pathway in Alzheimer's Disease Brain , 2003, Neurochemical Research.
[79] Á. Hernanz,et al. Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer’s disease Relationship with IL-6 concentrations , 2000, Brain Research.
[80] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[81] E. Levy,et al. Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. , 2010, Journal of Alzheimer's disease : JAD.
[82] S. Ghezzi,et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD , 2005, Journal of the Neurological Sciences.
[83] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[84] M. Sugishita,et al. [Clinical Dementia Rating (CDR)]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.
[85] P. Emson,et al. Relationship of calbindin D28K‐immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer's disease , 2001, Neuropathology : official journal of the Japanese Society of Neuropathology.
[86] Z. Janka,et al. Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia. , 2000, Acta neurologica Scandinavica.
[87] J. Kaye,et al. The FAS gene, brain volume, and disease progression in Alzheimer's disease , 2010, Alzheimer's & Dementia.
[88] K. Blennow,et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.
[89] J. Morris. The Clinical Dementia Rating (CDR) , 1993, Neurology.
[90] I. Sokal,et al. CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.
[91] K. Blennow,et al. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia , 2008, Neurobiology of Aging.
[92] L. Berg. Clinical Dementia Rating (CDR). , 1988, Psychopharmacology bulletin.
[93] Bernhard E. Boser,et al. A training algorithm for optimal margin classifiers , 1992, COLT '92.
[94] P. Matarrese,et al. Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: A pilot study , 2005, FEBS letters.
[95] F. Jessen,et al. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. , 2009, Journal of psychiatric research.
[96] Anders Wallin,et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. , 2009, Journal of Alzheimer's disease : JAD.
[97] Trey Sunderland,et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.
[98] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.